Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
InnoCan Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
InnoCan Pharma has a total shareholder equity of $6.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $8.7M and $2.7M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
Faiz karşılama oranı | n/a |
Nakit | US$5.19m |
Eşitlik | US$6.04m |
Toplam yükümlülükler | US$2.68m |
Toplam varlıklar | US$8.72m |
Son finansal sağlık güncellemeleri
We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely
Aug 09Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Dec 06We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth
Aug 15Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth
Apr 19Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Jul 20We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully
Apr 05Recent updates
We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely
Aug 09It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year
May 04Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Dec 06We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth
Aug 15Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth
Apr 19Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Jul 20We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully
Apr 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: INNO's short term assets ($8.6M) exceed its short term liabilities ($2.7M).
Uzun Vadeli Yükümlülükler: INNO's short term assets ($8.6M) exceed its long term liabilities ($4.0K).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: INNO is debt free.
Borcun Azaltılması: INNO has no debt compared to 5 years ago when its debt to equity ratio was 32.9%.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: INNO has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: INNO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 7.4% each year.